1
Stéphane De Lombaert
Raymond F Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, January 14, 2003: US06506762 (111 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stéphane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Pfizer, Neurogen Corporation, Ladas & Parry, May 20, 2003: US06566367 (53 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treat ...


3
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Darrow James W, de, Lombaert Stéphane, Zheng Xiaozhang: Substituted pyridin-2-ylamine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Darrow James W, de, Lombaert Stéphane, Zheng Xiaozhang, ALEXANDER John B, February 3, 2005: WO/2005/009980 (53 worldwide citation)

Substituted pyridin-2-ylamine analogues are provided, of the formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with patholog ...


4
Stéphane De Lombaert
Stéphane De Lombaert, Alan Hutchison, Xiaozhang Zheng: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Neurogen Corporation, Lawson & Weitzen, Sonia K Guterman, September 13, 2005: US06943199 (18 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a ...


5
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang, ALEXANDER John B, January 27, 2005: WO/2005/007648 (17 worldwide citation)

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with path ...


6
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, July 28, 2009: US07566712 (6 worldwide citation)

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic ...


7
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 10, 2009: US07488740 (5 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


8
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Caldwell Timothy M, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Caldwell Timothy M, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, ALEXANDER John B, January 27, 2005: WO/2005/007652 (5 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


9
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng, Taeyoung Yoon: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, December 4, 2007: US07304059 (3 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


10
Stéphane De Lombaert
Raymond F Horvath, Jennifer N Tran, Stéphane De Lombaert, Kevin J Hodgetts, Philip A Carpino, David A Griffith: Certain alkylene diamine-substituted heterocycles. Neurogen Corporation, Pfizer, Ladas & Parry, February 24, 2004: US06696445 (3 worldwide citation)

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY



Click the thumbnails below to visualize the patent trend.